AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8858633 — intervention group
Group type: COMPARATOR
Intervention: Topical mitomycin-C (0.05 mg/ml drops applied for 2 weeks postoperatively)
Number of subjects: 156
Study 1518497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 0
Study 1518497 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral antibiotic therapy (non-quinolone)
Number of subjects: 0
Study 6205676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of 0.1% solution of bleomycin sulphate in normal saline
Number of subjects: 24
Study 6205676 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 24
Study 29198993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) with post-exercise milk supplementation
Number of subjects: 53
Study 29198993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) with post-exercise milk-protein supplementation
Number of subjects: 53
Study 29198993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) with post-exercise placebo supplementation
Number of subjects: 53
Study 28817143 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine-derived xenograft collagen and collagen membrane
Number of subjects: 20
Study 28817143 — intervention group
Group type: COMPARATOR
Intervention: Natural spontaneous healing
Number of subjects: 20
Study 26654046 — intervention group
Group type: EXPERIMENTAL
Intervention: WAVES study obesity prevention intervention
Number of subjects: 92
Study 24084539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone followed by misoprostol (800 micrograms vaginally followed by 400 micrograms orally every 3 hours, max 4 doses)
Number of subjects: 142
Study 24084539 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone followed by oxytocin (high-concentration drip, max 150 milli-international units/min for up to 36 hours)
Number of subjects: 142
Study 24084539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone followed by misoprostol
Number of subjects: 142
Study 24084539 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone followed by oxytocin
Number of subjects: 142
Study 21122577 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg prednisone daily for two weeks prior to surveillance colonoscopy
Number of subjects: 60
Study 21122577 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 60
Study 18478482 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated perioperative care and rehabilitation intervention
Number of subjects: 87
Study 18478482 — intervention group
Group type: COMPARATOR
Intervention: Control group (current perioperative procedure)
Number of subjects: 87
Study 16009737 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 33
Study 16009737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 12705111 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration management intervention (fluid intake goal based on weight)
Number of subjects: 98
Study 12705111 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 98
Study 12705111 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration management intervention (with > or = 90% compliance)
Number of subjects: 98
Study 10832986 — intervention group
Group type: EXPERIMENTAL
Intervention: Operated eyes (LASIK)
Number of subjects: 28
Study 10832986 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (unoperated)
Number of subjects: 28
Study 8877677 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin capsules (0.5 to 120 mg)
Number of subjects: 22
Study 8877677 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin solution (0.5 to 120 mg)
Number of subjects: 22
Study 8877677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2005249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 64
Study 2005249 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 6361837 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 0
Study 6361837 — intervention group
Group type: COMPARATOR
Intervention: Exercise Training only
Number of subjects: 0
Study 30693746 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision robotic cholecystectomy (SIRC)
Number of subjects: 121
Study 30693746 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 121
Study 28415931 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80
Study 28415931 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study 28415931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 25112662 — intervention group
Group type: COMPARATOR
Intervention: CRT-D with BIV pacing <90%
Number of subjects: 1219
Study 25112662 — intervention group
Group type: COMPARATOR
Intervention: CRT-D with BIV pacing 91-96%
Number of subjects: 1219
Study 25112662 — intervention group
Group type: COMPARATOR
Intervention: CRT-D with BIV pacing >97%
Number of subjects: 1219
Study 25112662 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 1 percentage point increase in BIV pacing within CRT-D group
Number of subjects: 1219
Study 25112662 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing BIV pacing percentage
Number of subjects: 1219
Study 24214189 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 60 mg
Number of subjects: 48
Study 24214189 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 180 mg
Number of subjects: 48
Study 24214189 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 48
Study 24214189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 21061131 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucamesh®
Number of subjects: 50
Study 21061131 — intervention group
Group type: COMPARATOR
Intervention: Prolène®
Number of subjects: 50
Study 21061131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 19638921 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 27
Study 19638921 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 27
Study 18003554 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus (STN) stimulation
Number of subjects: 30
Study 18003554 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa administration
Number of subjects: 30
Study 18003554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of STN stimulation and L-dopa
Number of subjects: 30
Study 18003554 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 15476989 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education strategy (written booklet on health problems)
Number of subjects: 687
Study 15476989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 687
Study 11022827 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily for 3 weeks
Number of subjects: 31
Study 11022827 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 31
Study 11022827 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 9002496 — intervention group
Group type: EXPERIMENTAL
Intervention: Acadesine (0.1 mg·kg‐1·min‐1; intravenous infusion for 7 continuous hours and via the cardioplegia solution)
Number of subjects: 4043
Study 9002496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4043
Study 9002496 — intervention group
Group type: EXPERIMENTAL
Intervention: Acadesine
Number of subjects: 4043
Study 8455236 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravesical instillation of 80 mg epirubicin
Number of subjects: 431
Study 8455236 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 431
Study 2937434 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 50
Study 2937434 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 50
Study 30679293 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive-behavioural therapy (internet-CBT)
Number of subjects: 100
Study 30679293 — intervention group
Group type: COMPARATOR
Intervention: waitlist control
Number of subjects: 100
Study 28610945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention group (IG)
Number of subjects: 150
Study 28610945 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (CG)
Number of subjects: 150
Study 26703280 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 1.0%-ketorolac 0.3%
Number of subjects: 808
Study 26703280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study 23522518 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication with caregivers at a fourth-grade level on the Flesch-Kincaid scale.
Number of subjects: 47
Study 23522518 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased use of passive sentences in communication.
Number of subjects: 47
Study 23522518 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver understanding and comfort with administering pain medications.
Number of subjects: 47
Study 23522518 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver quality of life.
Number of subjects: 47
Study 23522518 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade level of talk with caregivers and hospice teams.
Number of subjects: 47
Study 21338818 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial mothering (15 min of vigorous physical and verbal stimulation conducted within 1 to 2h of birth and repeated 1 to 2h later)
Number of subjects: 41
Study 21338818 — intervention group
Group type: COMPARATOR
Intervention: No tactile or verbal stimulation other than that required for feeding (group 1)
Number of subjects: 41
Study 19493281 — intervention group
Group type: EXPERIMENTAL
Intervention: Victimization through sexual coercion by the husband (measured via CTS-2)
Number of subjects: 460
Study 19493281 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher conflict levels
Number of subjects: 460
Study 19493281 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-control and high violent socialization
Number of subjects: 460
Study 17912364 — intervention group
Group type: COMPARATOR
Intervention: 0% CO2
Number of subjects: 64
Study 17912364 — intervention group
Group type: EXPERIMENTAL
Intervention: 9% CO2
Number of subjects: 64
Study 17912364 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.5% CO2
Number of subjects: 64
Study 17912364 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2
Number of subjects: 64
Study 15447897 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (20 mg)
Number of subjects: 221
Study 15447897 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (20 mg)
Number of subjects: 221
Study 15447897 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron+Zinc
Number of subjects: 221
Study 15447897 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient mix (MM) of 16 vitamins and minerals including iron and zinc
Number of subjects: 221
Study 15447897 — intervention group
Group type: COMPARATOR
Intervention: Riboflavin
Number of subjects: 221
Study 11723368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study 9917449 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based management
Number of subjects: 63
Study 9917449 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based group (control)
Number of subjects: 63
Study 7479418 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 0
Study 7479418 — intervention group
Group type: COMPARATOR
Intervention: Low dose warfarin
Number of subjects: 0
Study 2156538 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrocortisone‐17‐alpha‐butyrate eardrops
Number of subjects: 46
Study 2156538 — intervention group
Group type: COMPARATOR
Intervention: oxytetracycline/hydrocortisone with polymyxin B (TPB)
Number of subjects: 46
Study 2156538 — intervention group
Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 46
Study 6107056 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide continued after operation (20 patients)
Number of subjects: 74
Study 6107056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide discontinued immediately after operation (30 patients)
Number of subjects: 74
Study 6107056 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam with nitrous oxide (24 patients)
Number of subjects: 74
Study 31686302 — intervention group
Group type: EXPERIMENTAL
Intervention: video‐recorded social contact
Number of subjects: 244
Study 31686302 — intervention group
Group type: EXPERIMENTAL
Intervention: audio/visual simulation
Number of subjects: 244
Study 31686302 — intervention group
Group type: COMPARATOR
Intervention: no intervention
Number of subjects: 244
Study 31116166 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index (OSDI) vision subscale
Number of subjects: 487
Study 31116166 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe meibomian gland plugging
Number of subjects: 487
Study 31116166 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructed meibomian glands
Number of subjects: 487
Study 31116166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear breakup time (TBUT) >5 seconds
Number of subjects: 487
Study 29193711 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 226
Study 29193711 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 226
Study 26218934 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasagital approach
Number of subjects: 56
Study 26218934 — intervention group
Group type: COMPARATOR
Intervention: Midline approach
Number of subjects: 56
Study 22801961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lintuzumab (600 mg) plus low-dose cytarabine (20 mg subcutaneously twice daily)
Number of subjects: 211
Study 22801961 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus low-dose cytarabine (20 mg subcutaneously twice daily)
Number of subjects: 211
Study 22801961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lintuzumab (600 mg)
Number of subjects: 211
Study 22801961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 22189801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (dietetic supplement during dialysis containing 355 kcal)
Number of subjects: 18
Study 22189801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 18
Study 22189801 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no intervention during the first three months)
Number of subjects: 18
Study 19573869 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery incision (EI)
Number of subjects: 62
Study 19573869 — intervention group
Group type: COMPARATOR
Intervention: Savary bougienage (SB)
Number of subjects: 62
Study 17123156 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanation of comparison questions in the pretest interview
Number of subjects: 65
Study 17123156 — intervention group
Group type: COMPARATOR
Intervention: No explanation of comparison questions
Number of subjects: 65
Study 17123156 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-discussing comparison questions between charts
Number of subjects: 65
Study 17123156 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective stress ratings due to relevant and comparison questions
Number of subjects: 65
Study 14645939 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use cessation and prevention interventions based on social influences and peer leader models.
Number of subjects: 44
Study 14645939 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 44
Study 10852998 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 973
Study 10852998 — intervention group
Group type: COMPARATOR
Intervention: Barium enema
Number of subjects: 973
Study 8850177 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65 g of n‐3 PUFA for 12 weeks
Number of subjects: 32
Study 8850177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1378116 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ibopamine
Number of subjects: 8
Study 1378116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6689676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 10
Study 6689676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 10
Study 6689676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 10
Study 6689676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg
Number of subjects: 10
Study 6689676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3763299 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing stuffed bear
Number of subjects: 0
Study 3763299 — intervention group
Group type: COMPARATOR
Intervention: No breathing bear (Control)
Number of subjects: 0
Study 3763299 — intervention group
Group type: COMPARATOR
Intervention: No bear (Control)
Number of subjects: 0
Study 30142795 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 68
Study 30142795 — intervention group
Group type: COMPARATOR
Intervention: Sham electro-acupuncture (sham-EA)
Number of subjects: 68
Study 27358643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 2 mg midazolam
Number of subjects: 40
Study 27358643 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 20 micrograms fentanyl
Number of subjects: 40
Study 24642345 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400mg
Number of subjects: 30
Study 24642345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24642345 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 30
Study 22546748 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-training aid (written and graphical descriptions of expert consensus standard)
Number of subjects: 165
Study 22546748 — intervention group
Group type: COMPARATOR
Intervention: Control group (instructions to continue with the task)
Number of subjects: 165
Study 21073703 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional physiotherapy and occupational therapy services on Saturday
Number of subjects: 712
Study 21073703 — intervention group
Group type: COMPARATOR
Intervention: Usual care physiotherapy and occupational therapy from Monday to Friday
Number of subjects: 712
Study 19260323 — intervention group
Group type: EXPERIMENTAL
Intervention: Puerarin with aspirin
Number of subjects: 45
Study 19260323 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment
Number of subjects: 45
Study 19260323 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 45
Study 15870588 — intervention group
Group type: EXPERIMENTAL
Intervention: Polestriding exercise training (24-week program, 3 times weekly)
Number of subjects: 49
Study 15870588 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise attention control group
Number of subjects: 49
Study 15870588 — intervention group
Group type: EXPERIMENTAL
Intervention: Polestriding exercise training
Number of subjects: 49
Study 14750378 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracapsular cataract extraction (ECCE)
Number of subjects: 60
Study 14750378 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification (PEA)
Number of subjects: 60
Study 14750378 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE
Number of subjects: 60
Study 10825304 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (esmolol infusions on the day of surgery and metoprolol for the next 48 hours)
Number of subjects: 107
Study 10825304 — intervention group
Group type: COMPARATOR
Intervention: Control (no beta-blockers)
Number of subjects: 107
Study 10825304 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 107
Study 10825304 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 107
Study 9003980 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak (1 micro Tesla), burst-firing magnetic fields applied for 20 min over the right temporoparietal lobe
Number of subjects: 0
Study 9003980 — intervention group
Group type: COMPARATOR
Intervention: Weak (1 micro Tesla), burst-firing magnetic fields applied for 20 min over the left temporoparietal lobe
Number of subjects: 0
Study 9003980 — intervention group
Group type: COMPARATOR
Intervention: Weak (1 micro Tesla), burst-firing magnetic fields applied for 20 min over both hemispheres
Number of subjects: 0
Study 9003980 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 1614196 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 microgram/kg)
Number of subjects: 83
Study 1614196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 6367018 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow graft with high dose cyclophosphamide and total body irradiation (8 Gray)
Number of subjects: 20
Study 31407421 — intervention group
Group type: EXPERIMENTAL
Intervention: Early jaw exercise intervention
Number of subjects: 0
Study 31407421 — intervention group
Group type: COMPARATOR
Intervention: Late jaw exercise intervention
Number of subjects: 0
Study 30335070 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of cortexin
Number of subjects: 189
Study 30335070 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of cortexin
Number of subjects: 189
Study 30335070 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment only
Number of subjects: 189
Study 30335070 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory data
Number of subjects: 189
Study 28091501 — intervention group
Group type: EXPERIMENTAL
Intervention: Rac-hopantenic acid (pantogam activ) at a daily dose of 1200 mg for 21 days
Number of subjects: 50